Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis
- PMID: 28201972
- DOI: 10.2174/1381612823666170214120708
Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis
Abstract
Cell-based tolerogenic therapy is a promising approach for the treatment of autoimmune diseases and transplant rejection. Regulatory T cells and tolerogenic dendritic cells have been particularly explored in the treatment of various autoimmune disorders in experimental models of disease. Although some of these cells have already been tested in a limited number of clinical trials, there is still a need for preclinical research on tolerogenic cells in animal models of autoimmunity. This review will focus on the relevance of data obtained from studies in experimental animal models for the use of tolerogenic cell-based therapy in humans. Also, perspectives for further improvement of tolerogenic cell preparation towards enhanced suppressive activity and stability of the cells will be discussed.
Keywords: Cell-based tolerogenic therapy; multiple sclerosis; regulatory T cells; rheumatoid arthritis; tolerogenic dendritic cells; type 1 diabetes.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Similar articles
-
Regulatory Macrophages and Tolerogenic Dendritic Cells in Myeloid Regulatory Cell-Based Therapies.Int J Mol Sci. 2021 Jul 26;22(15):7970. doi: 10.3390/ijms22157970. Int J Mol Sci. 2021. PMID: 34360736 Free PMC article. Review.
-
Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?Clin Exp Immunol. 2013 May;172(2):148-57. doi: 10.1111/cei.12038. Clin Exp Immunol. 2013. PMID: 23574312 Free PMC article. Review.
-
Tolerogenic dendritic cells and rheumatoid arthritis: current status and perspectives.Rheumatol Int. 2012 Apr;32(4):837-44. doi: 10.1007/s00296-011-2133-2. Epub 2011 Sep 9. Rheumatol Int. 2012. PMID: 21904923 Review.
-
Tolerogenic vaccines for the treatment of cardiovascular diseases.EBioMedicine. 2020 Jul;57:102827. doi: 10.1016/j.ebiom.2020.102827. Epub 2020 Jun 20. EBioMedicine. 2020. PMID: 32574952 Free PMC article. Review.
-
Inducing tissue specific tolerance in autoimmune disease with tolerogenic dendritic cells.Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 92):S97-103. Epub 2015 Oct 12. Clin Exp Rheumatol. 2015. PMID: 26458178 Review.
Cited by
-
Antigen Loading (e.g., Glutamic Acid Decarboxylase 65) of Tolerogenic DCs (tolDCs) Reduces Their Capacity to Prevent Diabetes in the Non-Obese Diabetes (NOD)-Severe Combined Immunodeficiency Model of Adoptive Cotransfer of Diabetes As Well As in NOD Mice.Front Immunol. 2018 Feb 16;9:290. doi: 10.3389/fimmu.2018.00290. eCollection 2018. Front Immunol. 2018. PMID: 29503651 Free PMC article.
-
Immunomodulating Hydrogels as Stealth Platform for Drug Delivery Applications.Pharmaceutics. 2022 Oct 21;14(10):2244. doi: 10.3390/pharmaceutics14102244. Pharmaceutics. 2022. PMID: 36297679 Free PMC article. Review.
-
Optimal Tolerogenic Dendritic Cells in Type 1 Diabetes (T1D) Therapy: What Can We Learn From Non-obese Diabetic (NOD) Mouse Models?Front Immunol. 2019 May 14;10:967. doi: 10.3389/fimmu.2019.00967. eCollection 2019. Front Immunol. 2019. PMID: 31139178 Free PMC article. Review.
-
Humanized Mouse Models of Rheumatoid Arthritis for Studies on Immunopathogenesis and Preclinical Testing of Cell-Based Therapies.Front Immunol. 2019 Feb 19;10:203. doi: 10.3389/fimmu.2019.00203. eCollection 2019. Front Immunol. 2019. PMID: 30837986 Free PMC article. Review.
-
The effect of immunomodulatory celecoxsib on the gene expression of inhibitory receptors in dendritic cells generated from monocyte cells.BMC Res Notes. 2025 Apr 13;18(1):164. doi: 10.1186/s13104-025-07226-y. BMC Res Notes. 2025. PMID: 40223111 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical